ID

31536

Descrizione

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00426777

collegamento

https://clinicaltrials.gov/show/NCT00426777

Keywords

versioni (1)
  1. 02/09/18 02/09/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

2 settembre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Prostate Cancer NCT00426777

Inglese

Eligibility Prostate Cancer NCT00426777

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients over 18 years of age.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
histologically confirmed diagnosis of prostate cancer without metastases.
Descrizione

Prostate carcinoma | Neoplasm Metastasis Absent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0600139
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0332197
patient must have negative bone scan to rule out bone metastases.
Descrizione

Bone scan Negative | Secondary malignant neoplasm of bone Rule out

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0203668
UMLS CUI [1,2]
C1513916
UMLS CUI [2,1]
C0153690
UMLS CUI [2,2]
C0332196
patient for whom androgen deprivation therapy with leuprolide acetate is indicated for at least 1 year.
Descrizione

Indication Antiandrogen therapy | Leuprolide Acetate

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C0279492
UMLS CUI [2]
C0700596
eastern cooperative oncology group (ecog) score of 0 - 2.
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
study medication must be started within 3 months of initiation of adt.
Descrizione

Start Investigational New Drugs | Initiation Antiandrogen therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0439659
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C1704686
UMLS CUI [2,2]
C0279492
signed written informed consent.
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior adt (greater than 3 months).
Descrizione

Antiandrogen therapy Previous

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279492
UMLS CUI [1,2]
C0205156
history of treatment with calcitriol or bisphosphonates.
Descrizione

Calcitriol | Diphosphonates

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006674
UMLS CUI [2]
C0012544
suppressive doses of thyroxine within the previous year.
Descrizione

Thyroxine Dose Suppressive

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0040165
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205367
concomitant or prior history of long-term treatment (greater than or equal to 3 months) with systemic glucocorticoids.
Descrizione

Systemic Glucocorticoids Long-term

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3540777
UMLS CUI [1,2]
C0443252
evidence of any of the following conditions per subject self-report or chart review:
Descrizione

Evidence of Condition Any

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0332120
UMLS CUI [1,2]
C0348080
UMLS CUI [1,3]
C1552551
current hyper- or hypothyroidism (stable on thyroid replacement therapy is allowed, if tsh is within normal reference range).
Descrizione

Hyperthyroidism | Hypothyroidism | Thyroid hormone replacement therapy Stable allowed | Relationship Serum TSH level normal

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0020550
UMLS CUI [2]
C0020676
UMLS CUI [3,1]
C2242640
UMLS CUI [3,2]
C0205360
UMLS CUI [3,3]
C0683607
UMLS CUI [4,1]
C0439849
UMLS CUI [4,2]
C0580433
paget's disease, cushing's disease, hyperprolactinemia, chronic liver disease. unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before randomization.
Descrizione

Paget Disease | Cushing's disease | Hyperprolactinemia | Chronic liver disease | Systemic disease Unstable | Communicable Disease | Uncontrolled hypertension | Angina, Unstable | Congestive heart failure | Myocardial Infarction

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1368019
UMLS CUI [2]
C0221406
UMLS CUI [3]
C0020514
UMLS CUI [4]
C0341439
UMLS CUI [5,1]
C0442893
UMLS CUI [5,2]
C0443343
UMLS CUI [6]
C0009450
UMLS CUI [7]
C1868885
UMLS CUI [8]
C0002965
UMLS CUI [9]
C0018802
UMLS CUI [10]
C0027051
major surgery or significant traumatic injury occurring within 1 month prior to randomization.
Descrizione

Major surgery | Traumatic injury

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C3263723
known hypersensitivity to leuprolide acetate or any of the components found in eligard
Descrizione

Hypersensitivity Leuprolide Acetate | Hypersensitivity Eligard Component

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0700596
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1170247
UMLS CUI [2,3]
C1705248
any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.
Descrizione

Condition Study Subject Participation Status Unfavorable | Condition compromises Protocol Compliance

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C3640815
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C2945640
UMLS CUI [2,3]
C0525058
Ritorna all'inizio della pagina

Similar models

Eligibility Prostate Cancer NCT00426777

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
patients over 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Prostate carcinoma | Neoplasm Metastasis Absent
Item
histologically confirmed diagnosis of prostate cancer without metastases.
boolean
C0600139 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Bone scan Negative | Secondary malignant neoplasm of bone Rule out
Item
patient must have negative bone scan to rule out bone metastases.
boolean
C0203668 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
C0153690 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
Indication Antiandrogen therapy | Leuprolide Acetate
Item
patient for whom androgen deprivation therapy with leuprolide acetate is indicated for at least 1 year.
boolean
C3146298 (UMLS CUI [1,1])
C0279492 (UMLS CUI [1,2])
C0700596 (UMLS CUI [2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) score of 0 - 2.
boolean
C1520224 (UMLS CUI [1])
Start Investigational New Drugs | Initiation Antiandrogen therapy
Item
study medication must be started within 3 months of initiation of adt.
boolean
C0439659 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C1704686 (UMLS CUI [2,1])
C0279492 (UMLS CUI [2,2])
Informed Consent
Item
signed written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Antiandrogen therapy Previous
Item
prior adt (greater than 3 months).
boolean
C0279492 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
Calcitriol | Diphosphonates
Item
history of treatment with calcitriol or bisphosphonates.
boolean
C0006674 (UMLS CUI [1])
C0012544 (UMLS CUI [2])
Thyroxine Dose Suppressive
Item
suppressive doses of thyroxine within the previous year.
boolean
C0040165 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205367 (UMLS CUI [1,3])
Systemic Glucocorticoids Long-term
Item
concomitant or prior history of long-term treatment (greater than or equal to 3 months) with systemic glucocorticoids.
boolean
C3540777 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
Evidence of Condition Any
Item
evidence of any of the following conditions per subject self-report or chart review:
boolean
C0332120 (UMLS CUI [1,1])
C0348080 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
Hyperthyroidism | Hypothyroidism | Thyroid hormone replacement therapy Stable allowed | Relationship Serum TSH level normal
Item
current hyper- or hypothyroidism (stable on thyroid replacement therapy is allowed, if tsh is within normal reference range).
boolean
C0020550 (UMLS CUI [1])
C0020676 (UMLS CUI [2])
C2242640 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
C0683607 (UMLS CUI [3,3])
C0439849 (UMLS CUI [4,1])
C0580433 (UMLS CUI [4,2])
Paget Disease | Cushing's disease | Hyperprolactinemia | Chronic liver disease | Systemic disease Unstable | Communicable Disease | Uncontrolled hypertension | Angina, Unstable | Congestive heart failure | Myocardial Infarction
Item
paget's disease, cushing's disease, hyperprolactinemia, chronic liver disease. unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before randomization.
boolean
C1368019 (UMLS CUI [1])
C0221406 (UMLS CUI [2])
C0020514 (UMLS CUI [3])
C0341439 (UMLS CUI [4])
C0442893 (UMLS CUI [5,1])
C0443343 (UMLS CUI [5,2])
C0009450 (UMLS CUI [6])
C1868885 (UMLS CUI [7])
C0002965 (UMLS CUI [8])
C0018802 (UMLS CUI [9])
C0027051 (UMLS CUI [10])
Major surgery | Traumatic injury
Item
major surgery or significant traumatic injury occurring within 1 month prior to randomization.
boolean
C0679637 (UMLS CUI [1])
C3263723 (UMLS CUI [2])
Hypersensitivity Leuprolide Acetate | Hypersensitivity Eligard Component
Item
known hypersensitivity to leuprolide acetate or any of the components found in eligard
boolean
C0020517 (UMLS CUI [1,1])
C0700596 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1170247 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Condition Study Subject Participation Status Unfavorable | Condition compromises Protocol Compliance
Item
any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.
boolean
C0348080 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C3640815 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial